Skip to main content

Advertisement

Table 2 Taxane-platinum (TP) versus platinum-based therapy (PC/PAC) in the TP53-negative and TP53-positive group. Interactions between the therapies and clinicopathological factors (multivariate models: the logistic regression and Cox proportional hazards model)*

From: TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

  TP53(-) group, N = 186 TP53(+) group, N = 266
  OR or HR [95% C.I.] P value OR or HR [95% C.I.] P value
Complete remission (CR)     
PC/PAC -   1.0  
TP - >0.1 3.28 [1.22,8.83] 0.018
endometrioid, CCC treated with PC/PAC 1.0   -  
endometrioid, CCC treated with TP >10 [0.92, +] 0.058 -  
Platinum sensitivity (PS)     
PC/PAC -   1.0  
TP - >0.1 1.96 [1.14, 3.35] 0.014
Platinum high sensitivity (PHS)     
PC/PAC 1.0   1.0  
TP 0.006 [0.001, 0.29] 0.010 10.73 [1.14, +] 0.038
endometrioid, CCC treated with PC/PAC 1.0   -  
endometrioid, CCC treated with TP 18.37 [1.25, +] 0.033 -  
FIGO IIIA/B treated with PC/PAC 1.0   -  
FIGO IIIA/B treated with TP 161 [3.08, +] 0.012 -  
FIGO IIIC treated with PC/PAC 1.0   -  
FIGO IIIC treated with TP 133 [2.94, +] 0.012 -  
Residual tumor >2 cm treated with PC/PAC -   1.0  
Residual tumor >2 cm treated with TP -   5.95 [1.16, +] 0.032
Grade 3 tumors treated with PC/PAC -   1.0  
Grade 3 tumors treated with TP -   0.11 [0.01, 1.14] 0.065
Grade 4 tumors treated with PC/PAC -   1.0  
Grade 4 tumors treated with TP -   0.04 [0.003, 0.55] 0.016
Disease free survival (DFS)     
PC/PAC versus TP   >0.1   >0.1
Overall survival (OS, risk of death)     
PC/PAC -   1.0  
TP - >0.1 0.15 [0.04, 0.60] 0.007
Age >53 treated with PC/PAC 1.0   1.0  
Age >53 treated with TP 0.51 [0.24, 1.08] 0.077 0.58 [0.32, 1.07] 0.080
Grade 3 tumors treated with PC/PAC -   1.0  
Grade 3 tumors treated with TP -   5.76 [1.44, 23.0] 0.013
Grade 4 tumors treated with PC/PAC -   1.0  
Grade 4 tumors treated with TP -   6.0 [1.43, 25.5] 0.015
  1. CCC – clear cell carcinoma; *this table shows only parameters which interacted with the chemotherapies; the clinical endpoints were also associated with other clinicopathological factors or their categories (see Table 3)